Aims Finerenone reduces the risk of cardiovascular events in patients with chronic kidney
disease (CKD) and type 2 diabetes (T2D). We investigated the causes of mortality in the …

Aims The complementary studies FIDELIO-DKD and FIGARO-DKD in patients with type 2
diabetes and chronic kidney disease (CKD) examined cardiovascular and kidney outcomes …

Background: The FIDELIO-DKD trial (Finerenone in Reducing Kidney Failure and Disease
Progression in Diabetic Kidney Disease) evaluated the effect of the nonsteroidal, selective …

Aims This prespecified analysis of the FIDELIO‐DKD trial compared the effects of
finerenone, a selective non‐steroidal mineralocorticoid receptor antagonist, on cardiorenal …

Background Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has
favorable effects on cardiorenal outcomes in patients with predominantly stage 3 or 4 …

Objective To evaluate the effect of finerenone on cardiovascular events in Kidney Disease
and/or Diabetes. Methods The ClinicalTrials. gov, Medline, EMBASE, Web of Science …

The purpose of this study is to assess the safety and efficacy of finerenone therapy in type 2
diabetes mellitus (T2DM) patients with cardiovascular and chronic renal diseases. This meta …

Background Patients with stage 4 CKD and type 2 diabetes have limited treatment options to
reduce their persistent cardiovascular and kidney risk. In Finerenone in Chronic Kidney …

Background Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist,
reduced albuminuria in short-term trials involving patients with chronic kidney disease …

Aims Finerenone, a selective, non-steroidal mineralocorticoid receptor antagonist, improves
cardiovascular (CV) and kidney outcomes in patients with type 2 diabetes (T2D) and chronic …